Phaseline

Companies › Sinovac Life Sciences

Sinovac Life Sciences: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 1, 1 Phase 3; Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sinovac PCV13
13-valent pneumococcal conjugate vaccine
–Phase 3Pneumococcal Infectious Disease–
Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose)
Hexavalent reassortant rotavirus attenuated live vaccine
–Phase 2Rotavirus GastroenteritisNov 2026
Sinovac PCV24
24-valent pneumococcal conjugate vaccine
–Phase 2Pneumococcal Infectious DiseaseDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06617715Sinovac PCV13Phase 3Pneumococcal Infectious DiseaseInfectious diseaseMay 2026
NCT06800261Sinovac PCV24Phase 1Pneumococcal Infectious DiseaseInfectious diseaseJun 2026
NCT06967272Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose)Phase 2Rotavirus GastroenteritisInfectious diseaseNov 2026
NCT06967272Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose)Phase 2Rotavirus GastroenteritisInfectious diseaseNov 2026
NCT07300644Sinovac PCV24Phase 2Pneumococcal Infectious DiseaseInfectious diseaseDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bharat Biotech International Green Cross Bavarian Nordic Osivax Artcline

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.